Key Developments For Medical Nutrition USA, Inc.
Medical Nutrition USA, Inc. (MDNU.O) (Consolidated Issue listed on NASDAQ Capital Market)
Medical Nutrition USA, Inc. Introduces Diff-Stat To Combat Antibiotic-Associated Intestinal Maladies
Medical Nutrition USA, Inc. announced the introduction of Diff-Stat, a new supplement containing pre- and probiotics to help restore and maintain beneficial bacteria that prevent the onset of antibiotic-associated diarrhea (AAD) and clostridium difficile (C-diff). C-diff is a bacterium that causes diarrhea and more serious intestinal conditions. It is one of the chief causes of hospital-acquired diarrhea in the U.S., responsible for approximately three million cases per year of diarrhea and colitis treated at an annual cost of more than $1.1 billion.
Medical Nutrition USA, Inc.'s Pro-Stat Improves Muscle Anabolism in Chronic Hemodialysis Patients
Medical Nutrition USA, Inc. announced the results of an independent randomized controlled, prospective study, conducted by a team of clinicians from Vanderbilt University Medical Center in Nashville, Tenn., and Fresenius Medical Care of North America, Waltham, MA, which demonstrated that chronic hemodialysis (CHD) patients had statistically significant improvements in total amino acids concentrations when taking Pro-Stat, a medical food providing 15 grams of concentrated protein per ounce. Patients were given Pro-Stat before and during hemodialysis and compared to a control group. Dialysis patients are at high risk for protein malnutrition since they lose protein with each treatment, have greater protein needs, often develop anorexia, taste disorders, and have an aversion to meat. If they are not consuming adequate calories and protein, their body begins breaking down muscle (catabolism) for energy and protein needs. The use of a protein supplementation for this population can significantly reduce the risk of protein malnutrition and may help improve overall health. Since these patients are also fluid restricted, typical larger dose reconstituted protein supplements (6-8 oz) are not appropriate. Pro-Stat was chosen for this study due to its small, one-ounce dose, rapidly absorbable hydrolyzed form, clinical record, and pleasant taste.
Medical Nutrition USA, Inc. Names Supplier By Amerinet Group Purchasing Organization
Medical Nutrition USA, Inc. announced it has been selected as a supplier by Amerinet Inc., a national group purchasing organization serving almost 5,800 healthcare institutions including long-term care, acute-care and alternate care facilities across the U.S. The supplier agreement provides that Amerinet member institutions will be able to purchase Medical Nutrition's Pro-Stat, Fiber-Stat and UTI-Stat product lines at the special prices that Amerinet has negotiated with distributors on behalf of its members. In addition, Amerinet will aid Medical Nutrition in marketing its products to the Amerinet membership.
Medical Nutrition USA, Inc. Signs Retail Licensing Deal With DSE
Medical Nutrition USA, Inc. announced that it has signed an exclusive agreement with DSE Healthcare Solutions, LLC to market its Proantinox product to U.S. retail outlets. The 10-year Trademark License Agreement gives DSE the right to utilize intellectual property, including trademarks, patents and formulation, relating to Proantinox, Medical Nutrition's urinary tract cleansing complex, in return for royalty payments based on sales to the retail market. Medical Nutrition will continue to market the product to the institutional market under the UTI-Stat brand.
Medical Nutrition USA, Inc. Reaffirms FY 2010 Revenue Guidance; Comments On Q2 2010 Revenue Guidance
Medical Nutrition USA, Inc. announced that it expects total revenue for fiscal 2010 to increase by approximately 16%-18% as a result of strong branded product sales offset by lower private label sales. Second quarter of 2009 sales are expected to grow by approximately 14%-16% compared to the second quarter of the prior year.
